ArticleIranian Red Crescent medical journal2012
The effect of selenium administration on restless leg syndrome treatment.
Article in Iranian Red Crescent medical journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- New horizons for the role of selenium on cognitive function: advances and challenges.Metabolic brain disease · 2024Review
- The Relationship between Serum Selenium Levels and Restless Leg Syndrome in Chronic Kidney Disease Patients.Medicina (Kaunas, Lithuania) · 2023Article
- Comment on "Evaluation of Serum Selenium Level, Quality of Sleep, and Life in Pregnant Women with Restless Legs Syndrome".Biological trace element research · 2023Article
- Serum Trace Elements Concentrations in Patients with Restless Legs Syndrome.Antioxidants (Basel, Switzerland) · 2022Article
- Mu opioid receptor knockout mouse: Phenotypes with implications on restless legs syndrome.Journal of neuroscience research · 2020Article
- Treatment of restless legs syndrome/Willis-Ekbom disease with selenium.Iranian journal of neurology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRestless leg syndrome (RLS) is defined as an uncomfortable feeling in the limbs which is prominently sensed in legs. Dopamine system involvement is considered as the base of RLS's etiology. Because of safety, anti-oxidant and dopaminergic promoting action of selenium, this study aims to investigate the effect of selenium on restless leg syndrome treatment.
methodsSixty patients with primary RLS were enrolled in this clinical trial (Irct2011103015943n1). It was based on 3 periods of drug prescription with one month wash out period. As placebo, 50 and 200 μg of selenium were administered in each separated month. The diagnosis was based on criteria published by IRLSG (International RLS Study Group). The questionnaire included 10 questions while each question's rating was between 0 and 4. Points between 1 and 10 were considered mild, 11 to 20 as moderate, 21 to 30 as severe and 31 to 40 as very severe. After end of each month of drug consumption, questionnaires were completed and each subject was asked to report the severity of disease and side effects of the drugs. At least 10 declines in scale were considered as appropriate responses.
resultsImprovement (decline IRLS score >10) was significantly higher in selenium (50 and 200 μg) than placebo group.
conclusionSelenium prescription in daily recommended dose of 50 μg instead of a dopamine agonist would be an alternative treatment in improvement of RLS symptoms.
Indexed as
Identifiers
22737548PMC3372025W2102548482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.